Epigenetics Group, International Agency for Research on Cancer (IARC), 69008 Lyon, France.
Genome Res. 2020 Oct;30(10):1517-1532. doi: 10.1101/gr.268292.120. Epub 2020 Sep 22.
The recent identification of recurrently mutated epigenetic regulator genes (ERGs) supports their critical role in tumorigenesis. We conducted a pan-cancer analysis integrating (epi)genome, transcriptome, and DNA methylome alterations in a curated list of 426 ERGs across 33 cancer types, comprising 10,845 tumor and 730 normal tissues. We found that, in addition to mutations, copy number alterations in ERGs were more frequent than previously anticipated and tightly linked to expression aberrations. Novel bioinformatics approaches, integrating the strengths of various driver prediction and multi-omics algorithms, and an orthogonal in vitro screen (CRISPR-Cas9) targeting all ERGs revealed genes with driver roles within and across malignancies and shared driver mechanisms operating across multiple cancer types and hallmarks. This is the largest and most comprehensive analysis thus far; it is also the first experimental effort to specifically identify ERG drivers (epidrivers) and characterize their deregulation and functional impact in oncogenic processes.
最近发现反复突变的表观遗传调控基因(ERGs)支持它们在肿瘤发生中的关键作用。我们对 33 种癌症类型中经过精心挑选的 426 个 ERGs 进行了泛癌症分析,整合了(表观)基因组、转录组和 DNA 甲基化组的改变,包括 10845 个肿瘤和 730 个正常组织。我们发现,除了突变之外,ERGs 的拷贝数改变比以前预期的更频繁,并且与表达异常密切相关。新的生物信息学方法,整合了各种驱动预测和多组学算法的优势,以及针对所有 ERGs 的正交体外筛选(CRISPR-Cas9),揭示了在癌症内部和之间具有驱动作用的基因,以及在多个癌症类型和特征中起作用的共享驱动机制。这是迄今为止最大和最全面的分析;这也是首次专门鉴定 ERG 驱动基因(epidrivers)并描述它们在致癌过程中的失调和功能影响的实验性努力。